Literature DB >> 6421627

Human menopausal gonadotropin stimulation in monkeys: blockade of the luteinizing hormone surge by a highly transient ovarian factor.

B A Littman, G D Hodgen.   

Abstract

Women and monkeys treated with human menopausal gonadotropin (hMG) often fail to demonstrate timely luteinizing hormone (LH) or follicle-stimulating hormone (FSH) surges despite serum estradiol (E2) levels sufficient to elicit positive feedback of LH and FSH secretion. Here we explored the mechanism of this blockade of estrogen-mediated positive feedback by hMG and the duration of this effect in acutely ovariectomized monkeys. Cycling cynomolgus monkeys (n = 14) were administered hMG (22.5 IU, intramuscularly) daily beginning on cycle day 3. Three monkeys received an E2-benzoate challenge on day 10, resulting in peak E2 levels of 892 +/- 313 pg/ml, without subsequent LH or FSH surges. Four monkeys underwent bilateral ovariectomy on day 12, followed within 60 to 90 minutes by gonadotropin-releasing hormone (GnRH) administration (15 micrograms, intravenously). Five intact monkeys underwent a similar GnRH challenge. LH response to GnRH in the intact monkeys was significantly suppressed in comparison with the ovariectomized group. None of the animals manifested an FSH response to GnRH administration. Two additional monkeys did have a spontaneous LH surge during hMG administration. We conclude that hMG stimulates the production of an ovarian factor(s) which blocks the pituitary LH response to GnRH. This blockade of GnRH action on the pituitary may be the mechanism by which hMG stimulation prevents estrogen-mediated positive feedback of LH secretion. The putative ovarian factor(s) has a relatively short circulatory half-life and/or binding time, resulting in loss of its blocking activity within 90 minutes after bilateral ovariectomy. Evidence is presented to suggest that this factor(s), designated gonadotropin surge-inhibiting factor, belongs to an amorphous group of nonsteroidal ovarian hormones that remain to be further characterized.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6421627     DOI: 10.1016/s0015-0282(16)47725-3

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

Review 1.  Gonadotropin surge-inhibiting/attenuating factors: a review of current evidence, potential applications, and future directions for research.

Authors:  Mario G Vega; Shvetha M Zarek; Medha Bhagwat; James H Segars
Journal:  Mol Reprod Dev       Date:  2015-01-12       Impact factor: 2.609

2.  Clinical aspects with regard to the occurrence of an endogenous luteinizing hormone surge in gonadotropin-induced normal menstrual cycles.

Authors:  J F Van Uem; J E Garcia; H C Liu; Z Rosenwaks
Journal:  J In Vitro Fert Embryo Transf       Date:  1986-12

3.  A randomized prospective study on the effect of short and long buserelin treatment in women with repeated unsuccessful in vitro fertilization (IVF) cycles due to inadequate ovarian response.

Authors:  M Dirnfeld; Y Gonen; A Lissak; S Goldman; M Koifman; Y Sorokin; H Abramovici
Journal:  J In Vitro Fert Embryo Transf       Date:  1991-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.